

Administration of RSV vaccines and monoclonal antibodies by age group or cohort

Age group or cohort	RSV vaccines for adults		RSV monoclonal antibodies for infants and children	
	Abrysvo® 0.5mL (Pfizer) 	Arexvy® 0.5 mL (GSK) 	Beyfortus™ (Nirsevimab) 0.5 mL (Purple) (Sanofi) 	Beyfortus™ (Nirsevimab) 1 mL (Blue) (Sanofi) 
Women from 28 weeks pregnancy	NIP FUNDED	DO NOT USE	DO NOT USE	DO NOT USE
Infants and children <24 months	DO NOT USE	DO NOT USE	STATE & TERRITORY FUNDED	STATE & TERRITORY FUNDED
Aboriginal and Torres Strait Islander people ≥60 years	AVAILABLE PRIVATELY BASED ON CLINICAL DECISION	NIP FUNDED	DO NOT USE	DO NOT USE
Adults 60-74 years (can consider vaccination)	AVAILABLE PRIVATELY BASED ON CLINICAL DECISION	AVAILABLE PRIVATELY BASED ON CLINICAL DECISION	DO NOT USE	DO NOT USE
Adults ≥75 years	AVAILABLE PRIVATELY BASED ON CLINICAL DECISION	NIP FUNDED	DO NOT USE	DO NOT USE
Adults 50-59 years with medical risk conditions that increase risk of severe RSV disease (can consider vaccination)	DO NOT USE	AVAILABLE PRIVATELY BASED ON CLINICAL DECISION	DO NOT USE	DO NOT USE
Adults ≥60 years with medical risk conditions that increase risk of severe RSV disease (recommended vaccination)	AVAILABLE PRIVATELY BASED ON CLINICAL DECISION	AVAILABLE PRIVATELY BASED ON CLINICAL DECISION	DO NOT USE	DO NOT USE

Note: NIP FUNDED indicates vaccine is NIP funded. **DO NOT USE** indicates product is **NOT** recommended for that group. **STATE & TERRITORY FUNDED** indicates funded under a state and territory program. **AVAILABLE PRIVATELY** indicates product only available through private prescription and is not funded. For further information including dosage and administration, refer to the Australian Immunisation Handbook chapter – [Respiratory syncytial virus \(RSV\)](#)